Compare AGNC Investment Corp (AGNC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs TransMedics Group Inc — how do they compare? AGNC Investment Corp trades at $10.89 (market cap $12.91B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: AGNC Investment Corp is far larger — about 4.2× TransMedics Group Inc's market cap, and AGNC Investment Corp pays a 13.22% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AGNC | TMDX | |
|---|---|---|
Market Cap | $12.91B | $3.10B |
Sector | Financials | Technology |
52-Week High | $12.17 | $150.42 |
52-Week Low | $9.46 | $61.99 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.925, up 1.53% today, with a bullish technical signal from moving averages. The mortgage REIT shows strong profitability with a 94.38% net income margin and 21.67% ROE, though it missed Q4 2025 EPS estimates. Recent analyst upgrades and consistent monthly dividends highlight income appeal, while the stock trades modestly above its $8.58 book value. Cash flow trends indicate active portfolio management with significant investing and financing activities.
Outlook: AGNC offers high yield income potential with a secure dividend history, but faces interest rate sensitivity and valuation constraints. Risks include mortgage spread volatility and leveraged portfolio exposure. Analyst consensus is mixed with a $11.30 price target suggesting limited upside from current levels.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
